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Abstract
Inflammation has classically been defined histopathologically, especially by the presence of immune cell infiltrates.
However, more recent studies suggest a role for "low-grade" inflammation in a variety of disorders ranging from metabolic
syndrome to cancer, which is defined by modest elevations in pro-inflammatory gene expression. Consequently, there is
a need for cost-effective, non-invasive biomarkers that, ideally, would have the sensitivity to detect low-grade inflammation
and have a dynamic range broad enough to reflect classic robust intestinal inflammation. Herein, we report that, for
assessment of intestinal inflammation, fecal lipocalin 2 (Lcn-2), measured by ELISA, serves this purpose. Specifically, using
a well-characterized mouse model of DSS colitis, we observed that fecal Lcn-2 and intestinal expression of pro-inflammatory
cytokines (IL-1b, CXCL1, TNFa) are modestly but significantly induced by very low concentrations of DSS (0.25 and 0.5%),
and become markedly elevated at higher concentrations of DSS (1.0 and 4.0%). As expected, careful histopathologic analysis
noted only modest immune infiltrates at low DSS concentration and robust colitis at higher DSS concentrations. In
accordance, increased levels of the neutrophil product myeloperoxidase (MPO) was only detected in mice given 1.0 and
4.0% DSS. In addition, fecal Lcn-2 marks the severity of spontaneous colitis development in IL-10 deficient mice. Unlike
histopathology, MPO, and q-RT-PCR, the assay of fecal Lcn-2 requires only a stool sample, permits measurement over time,
and can detect inflammation as early as 1 day following DSS administration. Thus, assay of fecal Lcn-2 by ELISA can function
as a non-invasive, sensitive, dynamic, stable and cost-effective means to monitor intestinal inflammation in mice.
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Introduction
The two major chronic inflammatory bowel diseases (IBD),
Crohn’s Disease (CD) and Ulcerative Colitis (UC), are character-
ized by acute to chronic inflammation of the gastrointestinal tract
affecting over a million individuals in the United States [1].
Although IBD etiology is obscure, significant evidence suggest that
inflammation results from aberrant immune responses to gut
microbiota in genetically susceptible host, which is also influenced
by other environmental triggers [2,3]. IBD patients are also at the
potential risk of developing intestinal neoplasias [4]. Currently,
clinical diagnosis of IBD is achieved through endoscopic
appearance and basic laboratory markers although cost, in-
vasiveness, and lack of specificity are acknowledged limitations [5].
Therefore there is a need for identification of potential sensitive
and non-invasive markers that can facilitate diagnosis before the
onset of clinical symptoms. In addition, it is increasingly
appreciated that low-grade chronic inflammation in the gut can
also promote metabolic disorders such as type II diabetes,
atherosclerosis and metabolic syndrome [6,7]. Thus, improved
identification of low-grade gut inflammation might be potentially
useful in researching, diagnosing, and/or treating IBD and
metabolic diseases.
Lipocalin 2 (Lcn-2) and its human counter part neutrophil
gelatinase-associated lipocalin (NGAL) belong to a family of small,
secreted proteins expressed by a variety of cells, the richest source
being neutrophils [8]. Results from our laboratory and others have
shown systemic upregulation of Lcn-2 (also known as siderocalin,
uterocalin and 24p3) in various murine models of colitis [9–11],
including human IBD [12]. In addition, human NGAL has been
reported to be increased in patients with ulcerative colitis [13].
Recently, it has been shown that Lcn-2 is real-time marker for
renal diseases and meets all the criteria required for a biomarker
[14,15]. The pro-inflammatory transcription factor NF-kB
transactivates Lcn-2 expression by binding to the consensus motif
within its promoter [16–18]. Expression of Lcn-2 in adipose tissue
is elevated in various experimental models of obesity and in obese
humans, suggesting that Lcn-2 may participate in inflammation-
related disorders [19–23].
In this study we investigated the extent to which fecal Lcn-2 can
serve as a sensitive and non-invasive biomarker of intestinal
inflammation using a well-studied murine models of dextran
sulfate sodium (DSS) induced colitis and spontaneous colitis in IL-
10 deficient mice. Our results demonstrate that fecal Lcn-2 levels
provide a stable, rapid, sensitive and broadly-dynamic means to
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non-invasively detect both low-grade inflammation and robust (i.e.
classic) colitis.
Methods
Mice
Eight weeks old male C57BL/6 and female IL-10 KO mice
were purchased from Jackson Laboratories. Mice were housed in
specific pathogen free conditions and fed ad libitum. Lcn-2KO mice
generated by Dr. Shizuo Akira (Japan) were obtained via Dr. Alan
Aderem (University of Washington).
Ethics Statement
Animal protocols were approved by institutional animal care
and use committee (Georgia State University Atlanta, GA), permit
number A11024.
DSS Induced Acute-colitis
Mice were administered DSS (MP Biomedicals, Solon, OH) at
0.25, 0.5, 1.0 and 4.0% in drinking water ad libitum for 7 days (5
mice per group). Control mice were given water only. During this
period, mice were weighed and feces were collected every day and
frozen at 220uC. After 7 days, mice were bled via retroorbital
plexus and hemolysis-free serum was collected by centrifugation
using serum separator tubes (BD Biosciences, Franklin Lakes, NJ).
Mice were sacrificed by CO2 euthanasia. Spleen and colon
weights and lengths were measured. A small piece (50 mg) of
proximal colon was taken for MPO analysis and RNA extraction,
and the rest of the colon fixed in 10% buffered formalin for
histological studies. For fecal Lcn-2 expression during mucosa
healing, mice were given 1.5% DSS in drinking water for 7 days
followed by 29 days of water without DSS prior to analysis of fecal
Lcn-2.
Fecal Lcn-2 in IL-10 KO Spontaneous Colitis
Eight-week-old (n = 20) female IL-10 KO mice and their BL6
WT controls were procured from Jackson Laboratories, housed in
GSU’s animal facility, and assayed for fecal Lcn-2 by ELISA after
12 weeks.
Quantification of Fecal and Serum Lcn-2 by ELISA
Freshly collected or frozen fecal samples were reconstituted in
PBS containing 0.1% Tween 20 (100 mg/ml) and vortexed for
20 min to get a homogenous fecal suspension. These samples
were then centrifuged for 10 min at 12,000 rpm and 4uC. Clear
supernatants were collected and stored at 220uC until analysis.
Lcn-2 levels were estimated in the supernatants using Duoset
murine Lcn-2 ELISA kit (R&D Systems, Minneapolis, MN).
Serum samples were diluted in kit-recommended reagent diluent
(1.0% BSA in PBS). Similarly treated Lcn-2KO mouse feces
and serum (control and DSS-treated mice) were used as
negative controls. For fecal Lcn-2 stability studies, freshly
collected feces were either frozen at 220uC or 4uC, stored at
room temperature for 24 h, or boiled for 1 h at 99uC before
being assayed.
qRT-PCR
Total RNA was isolated from colonic tissues using TRIzol
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. RNA were purified via precipitation with lithium
chloride, and quantitative RT-PCR were performed using the
Qiagen kit QuantiFastH SYBRH Green RT-PCR in a CFX96
apparatus (Bio-Rad,Hercules, CA) with specificmouse oligonucleo-
tides. The sense and antisense oligonucleotides used were, re-
spectively, the following: 36B4 59-TCCAGGCTTTGGGCATCA-
39 and 59-CTTTATTCAGCTGCACATCACTCAGA-39, TNF-
a 59-ACTCCAGGCGGTGCCTATGT-39 and 59-AGTGT-
GAGGGTCTGGGCCAT-39, KC 59-TTGTGCGAAAA-
GAAGTGCAG-39 and 59-TACAAACACAGCCTCCCACA-39,
IL-1b 59-TTGACGGACCCCAAAAGATG-39 and 59-
AGAAGGTGCTCATGTCCTCAT-39and Lcn-2 59-AAGG-
CAGCTTTACGATGTACAGC-39 and 59-CTTGCACATTG-
TAGCTGTGTACC-39. Results were normalized to the house-
keeping 36B4 gene.
Cytokine Analysis
Serum Keratinocyte derived-chemokine (KC) concentration
were determined using Duoset cytokine ELISA kits (R&D
Systems, Minneapolis, MN) according to manufacturer’s instruc-
tions.
Serum Lcn-2 Immunoblotting
Immunoblotting was performed as described [10]. Briefly,
serum was diluted (1:10) in 2X Laemmli sample buffer (Bio-Rad,
Hercules, CA) with b-mercaptoethanol, boiled for 5 min and
immediately cooled on ice for 10 min before being subjected to
SDS-PAGE on a 4–20% gel (Bio-Rad, Hercules, CA). Proteins
were transferred to nitrocellulose, blocked with 5% milk for 1 h,
probed with biotinylated anti-mouse Lcn-2 (0.2 ug/ml, R&D
Systems, Minneapolis, MN) overnight at 4uC, washed 3x and
probed with streptavidin HRP (Invitrogen, Carlsbad, CA) for 1 h
at RT. Immunoblots were developed by ECL (GE Healthcare,
Buckinghamshire, UK).
Colonic Myeloperoxidase (MPO) Assay
Neutrophil influx in tissue was analyzed by assaying the
enzymatic activity of MPO, a marker for neutrophils. Briefly,
tissue (50 mg/mL) was thoroughly washed in PBS and homoge-
nized in 0.5% hexadecyltrimethylammonium bromide (Sigma, St.
Louis, MO) in 50 mM PBS, (pH 6.0), freeze-thawed 3 times,
sonicated and centrifuged. MPO was assayed in the clear
supernatant by adding 1 mg/mL of dianisidine dihydrochloride
(Sigma, St. Louis, MO) and 561024% H2O2 and the change in
optical density measured at 450 nm. Human neutrophil MPO
(Sigma, St. Louis, MO) was used as standard. One unit of MPO
activity was defined as the amount that degraded 1.0 mmol of
peroxide/min at 25uC [24].
H&E Staining of Colonic Tissue and Histopathologic
Analysis
Following euthanasia, mouse colons were fixed in 10%
buffered formalin for 24 hours at room temperature and then
embedded in paraffin. Tissues were sectioned at 5-mm thickness
and stained with hematoxylin & eosin (H&E) using standard
protocols. H&E stained slides were scored by two pathologists
(A.N.Y. and M.A.D.). Each colon was assigned four scores
based on the degree of epithelial damage and inflammatory
infiltrate in the mucosa, submucosa and muscularis/serosa, as
previously described [25]. A slight modification was made to
this scoring system; each of the four scores was multiplied by 1
if the change was focal, 2 if it was patchy and 3 if it was
diffuse. The 4 individual scores per colon were added, resulting
in a total scoring range of 0–36 per mouse. The scores for each
of five mice per treatment group (i.e., exposed to 0, 0.25, 0.5,
1.0 and 4.0% DSS) were averaged.
Lcn-2: A Marker of Intestinal Inflammation
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Statistics
Statistical analysis for significance (p,0.05) was determined
using Student’s t-test (GraphPad Prism). Differences were noted as
significant * p,0.05.
Results
DSS-induced Gross Pathology is dose Dependent
The goal of this study was to investigate the utility of fecal Lcn-2
to serve as a non-invasive biomarker of intestinal inflammation.
Intestinal inflammation was induced by giving mice drinking water
with 1.0% and 4.0% DSS, which numerous studies have shown
induce moderate but easily appreciable and robust colitis,
respectively. Moreover, to attempt to induce low-grade inflam-
mation, mice were given doses of 0.25 and 0.5% DSS, both well
below those typically used to induce colitis in C57BL/6 mice. As
shown in figure 1A, after 7 days of DSS administration, the group
which received 4.0% DSS exhibited significant loss in body
weights, a hallmark feature of this model. Mice which were given
0.5 and 1.0% DSS showed modest decreases in body weight and
the group given 0.25% DSS is almost comparable to the control
group that received only water. Accordingly, the 4.0% DSS group
also exhibited other characteristic symptoms of DSS-induced
colitis, such as significant decrease in colon length and modest
increase in colon weight as well as splenomegaly (Figure 1 B–D),
a feature associated with anemia due to extensive rectal bleeding.
DSS Dose Dependent Elevation of Colonic and Systemic
Pro-inflammatory Gene Expression
Next, we analyzed pro-inflammatory gene expression in the
colon by qRT-PCR and serum cytokines by ELISA. In mice given
4.0% DSS, colonic KC levels were significantly upregulated at the
mRNA level (30-fold, Figure 2A), which was reflected by
concomitant elevation in systemic (i.e. serum) levels of the
neutrophil chemoattractant KC/CXCL1 (Figure 2B). KC levels,
a key mediator of neutrophil infiltration in the intestinal mucosa,
were modestly elevated in mice given 1.0% DSS whereas no
change in KC levels was observed either at the mRNA or protein
level in mice given lower doses of DSS (Figure 2 A–B). A similar
trend was observed for mRNA levels of the potent pro-
inflammatory cytokines TNF-a and IL-1b in the colon (Figure 2
C–D). In accordance with colonic and systemic KC levels, MPO
levels were significantly upregulated in the 4.0% DSS-treated
group, but only modestly elevated in mice given 1.0% and lower
doses of DSS (Figure 2E). Careful histological scoring of colonic
tissue, performed in a blinded fashion by 2 clinical pathologists
(A.N.Y. and M.A.D.) detected modest evidence of inflammation in
response to 0.25 and 0.5% DSS, whereas mice given 1.0% DSS
exhibited clear indications of immune cell infiltration accompa-
nied by epithelial ulceration and sub-mucosal thickening
(Figure 2F–G). As expected, mice given 4.0% DSS displayed
classic robust colitis marked by loss of epithelia and severe immune
cell infiltration. (Figure 2F–G).
Figure 1. DSS induced gross pathology is dose dependent. Eight week old male BL6 mice were administered DSS (0, 0.25, 0.5, 1.0, and 4.0%)
in drinking water for 7 days and monitored every day (5 mice per group). A, Loss in body weight; B, spleen weight; C, colon length and E, Colon
weight. * p,0.05.
doi:10.1371/journal.pone.0044328.g001
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Figure 2. DSS dose dependent increase in pro-inflammatory gene expression and histological damages. Colonic pro-inflammatory
cytokine-encoding genes were quantified by qRT-PCR (A, KC; C, TNF-a; D, IL-1b) and KC was quantified in the serum by ELISA (B). Colonic MPO were
determined (E), and H & E stained sections of the colon (F) were used for the determination of the histopathological score (G). * p,0.05.
doi:10.1371/journal.pone.0044328.g002
Lcn-2: A Marker of Intestinal Inflammation
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Correlation of Gut Inflammation with Expression of Lcn-2
Levels of serum Lcn-2 have previously been used as a marker
of inflammation [9,11]. In accordance, we observed a roughly
20-fold increase in levels of serum Lcn-2 in response to 4% DSS
and significant albeit lesser induction of this marker at lower DSS
concentrations (Figure 3A). No Lcn-2 was detected in control
sera or DSS-treated Lcn-2KO mice, verifying the specificity of
the commercially purchased immunoreagents used for this assay
(Figure 3A). We further verified our ELISA results by
immunoblotting, which picked up substantial upregulation of
serum Lcn-2 in mice given 4.0% and to a lesser extent in mice
given 1.0% DSS (Figure 3B). These results verify that serum
Lcn-2 can serve to detect robust intestinal inflammation but may
have only a limited ability to detect low-grade intestinal
inflammation. Consequently, we reasoned that measuring colonic
expression of Lcn-2 might provide more sensitivity in response to
DSS. In accordance with this notion, colonic expression of Lcn-
2 mRNA as measured by qRT-PCR increased by 3, 5, 10 and
100 fold relative to the control group in the colons of mice given
0.25, 0.5, 1.0 and 4.0% DSS (Figure 3C). Given that much of
the Lcn-2 produced by the intestine is made by intestinal
epithelial cells which secrete the majority into the intestinal
lumen [26], we hypothesized that DSS-induced intestinal Lcn-2
expression might be detectable in feces. Indeed, results presented
in figure 3D demonstrated that fecal Lcn-2 was a sensitive and
broadly dynamic marker of intestinal inflammation. Specifically,
fecal Lcn-2 was upregulated by over 10-fold in response to
0.25% DSS and 10,000 fold in response to 4.0% DSS. No Lcn-2
was detected in feces of Lcn-2KO mice (control or DSS-treated),
verifying the specificity of this assay. Next, to begin to investigate
the utility of fecal Lcn-2 to monitor intestinal inflammation with
minimal disturbance to mice, we measured the time course of
induction of fecal Lcn-2 in response to DSS. As shown in
figure 4, by day 1 fecal Lcn-2 levels significantly increased in all
groups of mice given DSS, regardless of dose. By day 3, fecal
Lcn-2 levels reached over 30- and 600-fold over controls in mice
given 1.0 and 4.0% DSS, respectively, and continued to increase
further in a dose- and time-dependent manner. Thus, fecal Lcn-2
is a sensitive marker capable of non-invasively detecting and
monitoring low-grade inflammation. Moreover, fecal Lcn-2 has
Figure 3. DSS induces Lcn-2 in a dose dependent manner. Serum Lcn-2 protein levels were analyzed by ELISA (A) and immunoblotting (B).
Colonic Lcn-2 mRNA levels were analyzed by qRT-PCR (C) and fecal Lcn-2 levels were measured in feces at day 7 by ELISA (D). *p,0.05.
doi:10.1371/journal.pone.0044328.g003
Figure 4. Substantial elevation of fecal Lcn-2 by DSS, in a time
and dose dependent manner. Fecal Lcn-2 levels were measured in
feces from day 0 through 7 by ELISA.
doi:10.1371/journal.pone.0044328.g004
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a broad dynamic range that allows discrimination between low-
grade and robust intestinal inflammation.
Fecal Lcn-2 Levels Marks the Severity of Spontaneous
Colitis in IL-10 KO Mice
We next examined fecal Lcn-2 levels in IL-10 KO mice, which
are prone to developing spontaneous colitis with the extent of
colitis exhibiting great variability in different vivaria [27]. Eight-
week-old female WT (BL6) and IL-10 KO mice were obtained
from Jackson Labs, housed in specific pathogen free conditions,
and monitored for colitis development for 12 weeks. After 12
weeks, fecal Lcn-2, colonic MPO and histology were evaluated.
While there was some variability in MPO levels of WT mice, all 20
mice were within 5 standard deviations (SD) of the mean in accord
with lack of evidence of colitis by histology. Analogously, fecal
Lcn-2 levels varied in WT mice but all were within 5 SD of the
mean. Thus, we viewed mice that had MPO of fecal Lcn-2 levels
greater than 5 SD above the mean of WT mice as being elevated.
Applying the cut-off derived from WT mice to IL-10-deficient
mice revealed 2 mice elevated MPO (figure 5A), which were
both exhibited histological signs of chronic inflammation with
striking immune cell infiltration and epithelial erosion (figure 5B).
These same 2 mice exhibited the highest levels of fecal Lcn-2,
which were .3000 fold elevated relative to mean levels of WT
mice thus indicating that measure of fecal Lcn-2 has ability to non-
invasively identify severely colitic IL-10 deficient mice
(figure 5C). However, several other IL-10 deficient mice had
fecal Lcn-2 greater than 5 SD above that of WT mice and all IL-
10-deficient mice had levels of fecal Lcn-2 greater than the mean
value of WT mice, indicating that fecal Lcn-2 levels also reflected
the low-grade inflammation variably reflected mild immune cell
infiltration. Thus fecal Lcn-2 is not only a sensitive marker for
chemical induced colitis but also reflects severity of inflammation
in a well-characterized immune-mediated colitis model.
Substantial Decrease in Fecal Lcn-2 during Mucosal
Healing
A necessary feature of a biomarker is rapid decrease in its levels
on cessation of disease/inflammation. Therefore, we monitored
fecal Lcn-2 levels during and after the termination of DSS in
drinking water. As shown in figure 6, fecal Lcn-2 increased
around 1000 fold following 7 days of DSS treatment. When DSS
was discontinued, allowing mucosal healing, Lcn-2 levels dramat-
ically decreased suggesting that fecal Lcn-2 exhibits this essential
property.
Fecal Lcn-2 is Stable
Another key feature of a valid biomarker is its stability during
storage, freezing-thawing and transportation. To address the
stability of fecal Lcn-2, we subjected fecal samples to a variety of
Figure 5. Fecal Lcn-2 marks the spontaneous colitis in IL-10 deficient mice. WT and IL-10 KO mice (n = 20) were analyzed for colonic MPO
(A), H & E stained colon (B) and fecal Lcn-2 (C). Red circle indicate colitic mice.
doi:10.1371/journal.pone.0044328.g005
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conditions including freezing at 220uC, storing at 4uC or ambient
room temperature (24uC) for 24 h or heating the samples to 99uC
for 10 min and quantified fecal Lcn-2 in those samples by ELISA.
The results indicated that no significant differences were observed
after storage at 4uC, or at room temperature for 24 h when
compared to 220uC, the temperature at which most clinical
samples are stored prior to testing (Figure 7). However, heating
the samples resulted in the loss of 95% ELISA reactivity. These
results demonstrate that fecal Lcn-2 is more than stable enough to
be used as an effective biomarker.
Discussion
Lipocalin-2 (Lcn-2), originally appreciated as being highly
abundant in neutrophils [8], has since been shown to be ubiquitously
expressed and be highly induced in response to a wide variety of pro-
inflammatory stimuli. Accordingly, levels of serum Lcn-2 have been
shown to be elevated in both classic inflammatory conditions such as
colitis and sepsis [11,28] and, moreover, in states of low-grade
inflammation such as metabolic syndrome, demonstrating that
serumLcn-2 could serve as amarker of inflammation [7].Given that
intestinal epithelial cells are one of the cell types in which Lcn-2 is
highly induced, and that in these cells most Lcn-2 is secreted apically
(i.e. luminally) [26], we hypothesized that fecal Lcn-2 might also
mark intestinal inflammation thus serving as a non-invasive
indicator of this state. Herein, we report that fecal Lcn-2, as assayed
by ELISA, was a stable, highly sensitive and broadly dynamic
marker of intestinal inflammation in mice. Specifically, fecal Lcn-2
was elevated by more than 10-fold in response to DSS concentra-
tions that induced low-grade/sub-clinical inflammation and elevat-
ed by over 10,000-fold in response to DSS concentrations that
induced histopathologically evident colitis. Such elevations in fecal
Lcn-2 correlated well with intestinal mRNA levels of Lcn-2 and
other pro-inflammatory genes, and thus fecal Lcn-2 can be viewed as
reflecting the extent of activation of pro-inflammatory gene
expression in the intestine. Thus, assay of fecal Lcn-2 can be used
not only to identify mice with robust, i.e. histopathologically evident
inflammation, but also to indicate low-grade or sub-clinical
inflammation.
Importantly, in contrast to assessing inflammation via histopa-
thology or by analysis of mRNA levels of pro-inflammatory genes
or systemic cytokines, use of fecal Lcn-2 as a marker of
inflammation is completely non-invasive and thus permits nearly
constant monitoring (e.g. hourly, daily) of individual mice. Indeed,
we used fecal Lcn-2 as a means to distinguish colitic and non-
colitic toll-like receptor 5 (TLR5) deficient mice, thus enabling us
to monitor the intestinal microbiota as colitis developed [29]. In
addition, fecal Lcn-2 also serves as a marker of intestinal
inflammation induced by the enteropathogen Adhesive-Invasive
E. coli (AIEC), first isolated from a Crohn’s disease patient [29].
As sample acquisition and preparation is very simple and stable,
we imagine a myriad of similar uses for this technique in basic
intestinal research including the investigation of intestinal epithe-
lial barrier dysfunction, increased gut bacterial burden/dysbiosis
and enteropathogen colonization. All requisite reagents for fecal
Lcn-2 assay via sandwich ELISA are commercially available at
low cost (0.35 $ per sample) when compared to commercially
existing stool biomarkers like calprotectin (6.70 $ per sample) [30],
HMGB1 (12.5 $ per sample) [31], or lactoferrin (6.75 $ per
sample) [32].
Thus, we expect that this technique will be widely adopted by
other researchers resulting in improved experimentation, reduced
numbers of mice per experiment, and concomitant reduced costs.
While relative levels of serum Lcn-2 parallel those in feces, the
extent of elevation of fecal Lcn-2 was much greater than that in
serum likely reflecting that the fecal parameter is more indicative
of conditions in the intestine. Consequently, it seems reasonable to
speculate assay of fecal Lcn-2 in humans might prove to have
clinical diagnostic value, perhaps as an early diagnostic marker
that might be used to suggest an infection or an inflammatory
bowel disease rather than the more common disease state of
irritable bowel syndrome, which is not associated with robust
inflammation. We anticipate that such questions will be a subject
of future research.
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